Erythromycin Ophthalmic 0.5% Ointment
Erythromycin ophthalmic 0.5% ointment is indicated for superficial bacterial conjunctivitis in adults (applied up to 6 times daily) and for neonatal prophylaxis against gonococcal and chlamydial ophthalmia (single 1 cm ribbon at birth), though its actual efficacy for chlamydial prevention is questionable and it should not be used alone in infants born to mothers with known gonorrhea. 1
Indications
Adults with Bacterial Conjunctivitis
- Treatment of superficial ocular infections involving the conjunctiva and/or cornea caused by erythromycin-susceptible organisms 1
- Presents typically with mucopurulent discharge and matted eyelids 2
Neonatal Prophylaxis
- Prevention of ophthalmia neonatorum due to N. gonorrhoeae or C. trachomatis 1
- Critical caveat: The FDA label explicitly states that effectiveness against penicillinase-producing N. gonorrhoeae is NOT established 1
- For infants born to mothers with clinically apparent gonorrhea, topical prophylaxis alone is inadequate—these infants require systemic ceftriaxone (25-50 mg/kg IV/IM, single dose, not exceeding 250 mg) 3, 1
Dosing Regimen
Bacterial Conjunctivitis in Adults
- Apply approximately 1 cm ribbon directly to infected eye(s)
- Frequency: Up to 6 times daily depending on infection severity 1
Neonatal Prophylaxis
- Apply 1 cm ribbon into each lower conjunctival sac
- Timing: Single application at birth 3, 1
- Do not flush the ointment from the eye after instillation 1
- Use a new tube for each infant to prevent cross-contamination 1
Contraindications
The FDA label does not list specific contraindications, but clinical judgment should consider:
- Known hypersensitivity to erythromycin or macrolide antibiotics
- Avoid in situations requiring treatment of penicillinase-producing gonococcal infections without systemic antibiotics 1
Important Clinical Caveats
Efficacy Concerns for Neonatal Prophylaxis
The evidence supporting erythromycin for neonatal prophylaxis is weak and contradictory:
- A 1980 study showed erythromycin prevented chlamydial conjunctivitis (0% vs 33% with silver nitrate) but did not significantly reduce nasopharyngeal infection or pneumonia 4
- However, a 1992 study found no significant difference in chlamydial conjunctivitis rates between erythromycin (1.5%), tetracycline (1.3%), silver nitrate (1.7%), and no prophylaxis (1.6%) 5
- Recent expert reviews argue that erythromycin is likely ineffective against gonococcal ophthalmia due to macrolide resistance development and is ineffective against chlamydial infection 6, 7
The Real Prevention Strategy
Prenatal screening and treatment of pregnant women for N. gonorrhoeae and C. trachomatis is far more effective than topical prophylaxis 6, 7. This became standard practice in the 1950s for gonorrhea and 1993 for chlamydia, which is why neonatal ophthalmia is now uncommon despite questionable prophylaxis efficacy.
Systemic Treatment Requirements
For neonates with confirmed ophthalmia neonatorum:
- Gonococcal: Ceftriaxone 25-50 mg/kg IV/IM (max 250 mg) single dose 3
- Chlamydial: Erythromycin base or ethylsuccinate 50 mg/kg/day orally divided into 4 doses for 14 days, OR azithromycin suspension 20 mg/kg/day orally once daily for 3 days 3